论文部分内容阅读
IgE类型的抗体是过敏性疾病的始动因素,抗IgE抗体能特异性地识别并结合游离IgE分子,下调IgE分子水平,人源化抗IgE单克隆抗体的出现更是为过敏性疾病带来了新的治疗方法。临床研究治疗哮喘、过敏性鼻炎以及食物过敏症等疾病中获得的大量数据更显示了其良好的疗效。与传统临床治疗手段相比,人源化抗IgE抗体具有副作用小,安全性高等优点。此外,治疗过敏性疾病的拮抗分子的研究也十分盛行。在分析IgE分子功能表位的基础上进行适当的分子设计可获得潜在的治疗过敏性疾病的拮抗剂如抗IgE抗体类似多肽、IgE类似肽以及其他抑制性小分子等。
IgE type antibody is the initiating factor of allergic diseases, anti-IgE antibodies can specifically recognize and bind to free IgE molecules, down-regulation of IgE levels, the emergence of humanized anti-IgE monoclonal antibody is more for allergic diseases The new treatment. Clinical research to treat asthma, allergic rhinitis and food allergies and other diseases obtained a large number of data more shows its good effect. Compared with the traditional clinical treatment, humanized anti-IgE antibody has the advantages of less side effects, higher safety. In addition, the research on antagonistic molecules for the treatment of allergic diseases is also very prevalent. Based on the analysis of functional epitopes of IgE molecules, suitable molecular design can obtain potential antagonists for allergic diseases such as anti-IgE antibody-like peptides, IgE-like peptides and other small inhibitory molecules.